Citations 1
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
Martin, Thomas G. , Vij, Ravi , Cole, Craig E. , Atanackovic, Djordje , Zonder, Jeffrey A. , Bensinger, William, Zimmerman, Todd M., Lendvai, Nikoletta , Gasparetto, Cristina , Kumar, Shaji , Oprea, Corina, Richter, Joshua , Kaufman, Jonathan L. , Mıkhael, Joseph , Dimopoulos, Meletios Α. , Hari, Parameswaran , Ocio, Enrique M. , Charpentier, Éric , Strickland, Stephen Anthony , Miguel, Jesús F. San
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8005-8005
